Amdinocillin use while Breastfeeding
Medically reviewed by Drugs.com. Last updated on Dec 21, 2023.
Amdinocillin Levels and Effects while Breastfeeding
Summary of Use during Lactation
Amdinocillin (pivmecillinam; the pivaloyl ester of mecillinam) is not commercially available in the United States, but is marketed internationally. Limited information indicates that amdinocillin produces low levels in milk that are not expected to cause adverse effects in breastfed infants. Monitor the breastfed infant for diarrhea and thrush.
Drug Levels
Maternal Levels. Four women who were 4 or 6 days postpartum were given a single 100 mg dose of amdinocillin. The drug was not detectable in breastmilk 1 or 3 hours after the dose, although the sensitivity of the assay is unknown.[1]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
-
Seiga K, Minagawa M, Yamaji K, et al. Studies on pivmecillinam. Chemotherapy (Tokyo). 1977;25:347–51. [CrossRef]
Substance Identification
Substance Name
Amdinocillin
CAS Registry Number
32886-97-8
Drug Class
Breast Feeding
Lactation
Milk, Human
Anti-Infective Agents, Urinary
Anti-Bacterial Agents
Beta-Lactams
Penicillins
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.